Skin analysis and skin cancer prevention, why 3D topography is not a screening substitute

When an aesthetic or dermatology practice deploys 3D skin analysis, patients often ask as an aside: "Can you also see whether I have a dangerous mole?" The honest answer is no. This article explains why, and where the method nevertheless legitimately complements the prevention chain. Failing to separate the topic carries two risks: medical-device-law misuse (the software becomes de-facto Class IIa/IIb diagnostic) and a trust break in the patient relationship.

What statutory skin-cancer screening is

In Germany, statutorily insured persons aged 35+ have a biennial entitlement to skin-cancer screening (§ 25 SGB V in conjunction with the Cancer Early Detection Directive). Content: standardised full-body inspection by a GP or dermatologist with skin-cancer screening certification. Dermatoscopy (epiluminescence microscopy) is not part of the statutory standard screening but an additional IGeL service.

The scoring scheme is the classical ABCDE rule: Asymmetry, Border, Colour, Diameter, Evolution. Combined with dermatoscopic patterns (globular, reticular, streaks, pseudopods, etc.) it provides the diagnostic basis for suspected melanoma.

What 3D skin analysis with UV spectrum does

Devices like the Isemeco D8 or D9 are CE-certified as Class I medical devices (purely optical imaging). They capture RGB, UV and polarised images of the face and generate a 3D mesh of the skin surface. The algorithms quantify pigment clusters, wrinkle depth, pore count, redness area. They do no ABCDE evaluation, no dermatoscopic pattern recognition and no suspicion-diagnosis statement.

Concretely: a solar lentigo, a lentigo maligna and a dysplastic nevus can look similar in the UV image. The software does not know that, it counts the pigment area as "UV marker". Anyone working without accompanying clinical inspection misses the first-second differential diagnosis.

What Dermalia explicitly does not do

The Dermalia report contains no suspicion diagnoses and no melanoma hints. We have explicitly excluded this in our MDR self-assessment: Dermalia is a report-presentation layer for the score values delivered by the device, not diagnostic-supporting software. The AI Q&A component has refusal detection for emergency keywords such as "melanoma", "cancer", "tumour", "bleeding" and refers to the medical consultation, it generates no suspicion claims.

Where skin analysis legitimately complements prevention

Three scenarios are in our view clearly separated from screening and useful:

• UV damage visualisation for patient education: the UV capture shows accentuated epidermal pigment clusters that are subtle in visible light. This is a visual anchor for sunscreen counselling. Not diagnostic, an educational tool.
• Tracking aesthetic interventions: for IPL or Q-switched laser pigment reduction the report shows the score change. The indication lentigo maligna should however be excluded dermatoscopically before the treatment.
• Patient communication around anti-aging: the primary application of 3D skin analysis. Prevention and report are methodologically clearly separated here.

What practices should avoid in communication

• "Skin cancer early detection with 3D scan": wrong intended purpose under MDR, because a Class I device does not carry the diagnostic task. Nothing in this direction on the practice website.
• "AI-supported melanoma detection": there is AI software for dermatoscopy that does this, it is Class IIa or IIb certified. A cosmetic 3D skin analysis is not.
• "We check every mole": that is the task of dermatological screening, not skin analysis software. Clean linguistic separation protects against liability and strengthens patient trust.

A clean phrasing in the patient conversation: "This skin analysis shows pigment, wrinkle and redness values. It does not replace the medical skin-cancer screening. If you notice a suspicious mole, please schedule a skin-cancer screening appointment."

When a practice needs a different device

A practice actively pursuing melanoma suspicion needs a dermatoscopic device (handheld dermatoscope or digital epiluminescence-microscopy system) and possibly sequential digital dermatoscopy software certified as Class IIa. Examples are FotoFinder, Heine Delta, Canfield VECTRA with total-body photography. These devices are not in competition with 3D skin analysis, they sit in a different indication and a different MDR class.

Sources and further reading

• German Cancer Information Service on skin-cancer screening and the ABCDE rule: krebsinformationsdienst.de/hautkrebs
• Skin Cancer Network Germany e.V., ABCDE rule: hautkrebs-netzwerk.de/abcd-regel
• MDCG 2019-11 Rev.1 (software classification under MDR): health.ec.europa.eu/MDCG 2019-11
• Cancer Early Detection Directive of the Federal Joint Committee (G-BA): g-ba.de

As of May 2026. This article is orientational professional information for practices, not medical-law advice in the individual case. Concrete intended-purpose and classification questions belong with a specialist medical-law attorney.